Table 5.
Position of detectable cancerous lesions in [18F]PSMA-1007 PET/CT patients (pretreated with radical prostatectomy/F-RP) with relation to PSA.
| PSA (ng/mL) | 0.2 -< 0.5 | 0.5 -< 1.0 | 1.0 -< 2.0 | 2.0 -< 5.0 | ≥5.0 | Chi2, r |
|---|---|---|---|---|---|---|
| Number (x/78) patient group F-RP |
17 | 17 | 17 | 13 | 14 | |
| PET/CT positive | 11/64.7% | 16/94.1% | 15/88.2% | 13/100% | 14/100% |
p = 0.009 r = 0.340 |
| Local recurrence without metastases |
5 | 1 | 3 | 2 | 0 | |
| Local recurrence with local metastases (regional metastases in the pelvis: iliac and/or pararectal) |
0 | 1 | 1 | 1 | 1 | |
| Local metastases without local recurrence | 4 | 3 | 2 | 0 | 0 | |
| Local recurrence with distant metastases (within 2 regions) | 0 | 1 | 0 | 0 | 1 | |
| Distant metastases (within 2 regions) without local recurrence | 1 | 2 | 1 | 1 | 0 | |
| Local recurrence with multiple metastases | 0 | 2 | 3 | 4 | 2 | |
| Multiple metastases without local recurrence | 1 | 6 | 5 | 5 | 10 | |
| Number of metastases: |
p = 0.001 r = 0.522 |
|||||
| Single metastases | 5 | 7 | 4 | 2 | 2 | |
| Multiple metastases | 1 | 8 | 8 | 9 | 12 | |
| Lymph node metastases (LNM) |
5 | 12 | 10 | 9 | 9 |
p = 0.103 r = 0.200 |
| Site of LNM: |
p = 0.121 * r = 0.333 |
|||||
| Local LNM (regional LNM in the pelvis: iliac and/or pararectal) |
5 | 10 | 8 | 6 | 4 | |
| Distant LNM (extrapelvic LNM: retroperitoneal and/or above the iliac bifurcation) |
0 | 1 | 1 | 0 | 1 | |
| Local + distant LNM | 0 | 1 | 1 | 3 | 4 | |
| Bone metastases | 1 | 3 | 4 | 4 | 9 |
p = 0.007 * r = 0.407 |
| Visceral metastases | 0 | 0 | 0 | 0 | 0 |
* Fisher exact test. Abbreviations: PSA, prostate-specific antigen; LNM, lymph node metastases; p-value < 0.05 is considered significant; r, Pearson correlation coefficient.